FDA issued final guidance on dissolution testing for manufacturers submitting drug applications that describes when a standard release test and criteria may be used in lieu of extensive method development. The guidance provides acceptance criteria-setting exercises for orally administered immediate-release (IR) drug products that contain highly soluble drug substances.
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
